10-K: Citius Pharma's 2025 Annual Report: LYMPHIR Launch, Financial Challenges

Citius Pharmaceuticals, Inc. reports a net loss of $39.7 million for fiscal year 2025, with its subsidiary Citius Oncology launching LYMPHIR amidst ongoing funding needs and product development.

Summary

• Citius Pharma is a biopharmaceutical company focused on critical care products, oncology, anti-infectives, and stem cell therapies.
• Its majority-owned subsidiary, Citius Oncology, launched LYMPHIR (denileukin diftitox) in December 2025 for persistent or recurrent cutaneous T-cell lymphoma (CTCL) after FDA approval in August 2024.
• LYMPHIR's Phase 3 trial (E7777-G000-302) met objectives with an Objective Response Rate (ORR) of 36.2% and a comparable safety profile to the prior formulation.
• Preliminary Phase 1 results for LYMPHIR combined with pembrolizumab in solid tumors showed an ORR of 27% and a clinical benefit rate of 33%.
• Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections (CRBSIs), met its primary endpoint in Phase 3 with statistically significant improvement in time to catheter failure and 57% catheter retention.
• Halo-Lido, a topical formulation for hemorrhoids, showed positive Phase 2b results, with 42% of high-dose patients reaching a Meaningful Change Threshold (MCT).
• NoveCite, a mesenchymal stem cell therapy for ARDS, is in preclinical stage, with development paused to prioritize LYMPHIR.
• The company reported a net loss of $39.7 million for FY2025, an accumulated deficit of $238.8 million, and negative working capital of approximately $17 million.
• Substantial doubt exists about the company's ability to continue as a going concern beyond March 2026 without additional funding.
• Significant milestone payments are due for LYMPHIR: $19.75 million to Dr. Reddys and $2.9 million to Eisai as of September 30, 2025.
• The company raised $6.0 million in October 2025 and Citius Oncology raised $18.0 million in December 2025.

Sentiment

Score: 3

Explanation: While there are positive clinical developments and a product launch, the company faces significant financial challenges, including recurring losses, negative working capital, substantial debt, and a going concern warning, indicating high financial risk despite operational progress.

Positives

• FDA approval of LYMPHIR in August 2024 and its commercial launch in December 2025.
• Positive topline results from the Mino-Lok Phase 3 trial, meeting its primary endpoint with statistically significant improvement in time to catheter failure.
• Mino-Lok received Fast Track designation and Qualified Infectious Disease Product (QIDP) designation, potentially granting 8 years of market exclusivity.
• Positive preliminary Phase 1 results for LYMPHIR in combination with pembrolizumab for recurrent solid tumors, showing a 27% ORR and 33% clinical benefit rate.
• Positive Phase 2b results for Halo-Lido, with 42% of high-dose patients achieving a Meaningful Change Threshold.
• LYMPHIR's inclusion in National Comprehensive Cancer Network (NCCN) guidelines (Category 2A recommendation).
• CMS assigned a unique, permanent HCPCS J-code (J9161) to LYMPHIR, facilitating reimbursement.
• Successful capital raises in October and December 2025, providing funds through March 2026.

Negatives

• Net loss of $39,740,269 for the year ended September 30, 2025.
• Accumulated deficit of $238,804,129 as of September 30, 2025.
• Negative working capital of approximately $17 million at September 30, 2025.
• Independent registered public accounting firm's report includes an explanatory paragraph stating substantial doubt about the ability to continue as a going concern beyond March 2026.
• Requires substantial additional funding to support operations, complete LYMPHIR commercialization, and continue other product development.
• Significant outstanding milestone payments: $19.75 million to Dr. Reddys and $2.9 million to Eisai for LYMPHIR as of September 30, 2025.
• Outstanding purchase commitments of approximately $16.2 million for drug substance and $4.9 million for finished drug products.
• History of net losses since inception and expectation to incur losses for the foreseeable future.
• Market price of common stock is highly volatile, and the company has faced Nasdaq delisting notifications multiple times.
• Development of NoveCite (stem cell therapy) has been paused to prioritize LYMPHIR.

Risks

• Substantial doubt about the ability to continue as a going concern.
• Need for substantial additional funding, which may not be available on acceptable terms or at all.
• History of net losses and expectation to incur losses for the foreseeable future; may never achieve profitability.
• Exploration of alternative strategic paths may not result in completing a transaction, or the process could adversely affect stock price.
• If a strategic transaction is not completed, the Board may decide to pursue dissolution and liquidation.
• Heavy dependence on the launch and commercial success of LYMPHIR.
• Unproven business strategy and limited operating history for commercialization of LYMPHIR or other product candidates.
• Guarantor of milestone payments to licensor and former licensee of LYMPHIR intellectual property, which could adversely affect profitability.
• Material breach under license agreements (e.g., timely payment) could lead to termination of license.
• Failure to abide by contractual obligations with third-party manufacturers/suppliers could result in loss of support.
• Significant risks in development and commercialization efforts of LYMPHIR and other product candidates.
• May choose not to continue developing any product candidates, reducing or eliminating return on investment.
• Significant risk to successfully developing a late-stage product candidate despite strategy.
• Inability to file for approval of Mino-Lok or Halo-Lido under Section 505(b)(2) or requirement for additional data could delay timelines.
• Approval under Section 505(b)(2) for Mino-Lok/Halo-Lido would not preclude physicians/patients from obtaining individual drug products and titrating dosage.
• Fast track designation or priority review status may not lead to faster development/approval or assure FDA approval.
• Does not own Citius Oncology or NoveCite outright, sharing benefits with other stockholders.
• Even if regulatory approval is received, products may not gain market acceptance or generate significant revenue.
• Failure to establish marketing, sales, and distribution capabilities (on its own or through third parties) could prevent market creation.
• Projections regarding market opportunity for LYMPHIR and other product candidates may not be accurate.
• Highly competitive markets; may be unable to compete successfully.
• Product revenues diminished if approved products sell for inadequate prices or patients cannot obtain adequate reimbursement.
• Healthcare reform measures could hinder or prevent commercial success.
• Dependence on third-party contract research organizations for clinical trials.
• Exclusive reliance on third parties to formulate and manufacture product candidates.
• Termination, breach by, or conflict with strategic partners could harm business.
• Reliance on specialized expertise of executive management and key personnel; loss or inability to hire successors could harm business.
• Inability to retain or hire additional qualified personnel could harm business growth.
• Subject to information technology and cyber-security threats.
• Results of pre-clinical studies and completed clinical trials are not necessarily predictive of future results.
• Conflicts of interest may arise from relationships with Citius Oncology and NoveCite.
• Might not obtain necessary U.S. or foreign regulatory approvals for current product candidates.
• Subject to ongoing regulatory obligations and restrictions post-approval, resulting in significant expense and limiting commercialization.
• Could be forced to pay substantial damage awards if product liability claims are successful.
• Failure to protect intellectual property may adversely affect business; may suffer if infringing third-party rights.
• U.S. government could have march-in rights to certain intellectual property.
• May be unable to achieve some or all benefits expected from the Citius Oncology Merger.
• Planned distribution of Citius Oncology shares could result in significant tax liability to Citius Pharma and stockholders.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting.
• Market price of common stock is highly volatile; may lose some or all investment.
• Dilution of ownership interests due to future issuance of additional shares or convertible securities.
• Certificate of Incorporation allows Board to create new series of preferred stock without stockholder approval, adversely affecting common stockholders' rights.
• No cash dividends paid in the past, not expected in the foreseeable future.
• Provisions in Amended and Restated Articles of Incorporation and Nevada law could discourage takeovers.
• Incorrect estimates or judgments relating to critical accounting policies could adversely affect results.

Future Outlook

The company expects to incur operating losses for the foreseeable future and requires substantial additional funding beyond March 2026. Success depends heavily on LYMPHIR's commercialization and obtaining regulatory approval for Mino-Lok. The company is evaluating strategic alternatives including partnerships, joint ventures, mergers, acquisitions, or licensing transactions to secure necessary resources and maximize stockholder value.

Management Comments

• We believe these unique markets for our products are large, growing, and underserved by the current prescription products or procedures.
• We believe that Mino-Lok would be cost-saving to the healthcare system given that the removal of an infected CVC and replacement of a new catheter in a different venous access site is estimated by us to cost between $8,000 and $10,000.
• We believe there will be an economic argument to enhance the adoption of Mino-Lok by infection control committees at acute care institutions.
• We believe that a novel topical formulation of halobetasol propionate and lidocaine designed to provide anti-inflammatory and anesthetic relief and which has an FDA-approved label specifically claiming the treatment of hemorrhoids will become an important treatment option for physicians who want to provide their patients with a therapy that has demonstrated safety and efficacy in treating this uncomfortable and often recurring disease.
• We believe that our Halo-Lido product represents an attractive, low-risk product opportunity with meaningful upside potential.
• We believe [NoveCite iMSCs] to be differentiated and superior to donor-derived MSCs.
• Our management believes that inflation has not had a material effect on our results of operations.

Industry Context

The company operates in the highly competitive biopharmaceutical industry, focusing on critical care, oncology, and anti-infectives. LYMPHIR targets CTCL, an underserved market with existing therapies having limitations. Mino-Lok addresses CRBSIs, where no FDA-approved salvage alternative exists. Halo-Lido aims to be the first FDA-approved prescription product for hemorrhoids in a fragmented market dominated by OTCs. NoveCite is in the novel and uncertain field of iPSC-derived cell therapies for ARDS.

Comparison to Industry Standards

• LYMPHIR's Phase 3 safety profile is comparable to Study 93-04-11/L4389-11, which served as the basis for ONTAK's full approval.
• Mino-Lok's 100% efficacy in salvaging CVCs in Phase 2b demonstrated equal effectiveness to removing and replacing infected CVCs, with a better safety profile (0% SAEs vs. 18% SAEs in control).
• The Mino-Lok Phase 3 trial's new primary endpoint requires time to catheter failure to be at least 38 days for Mino-Lok versus 21 days for standard of care antibiotic locks.
• Halo-Lido aims to be the first FDA-approved prescription drug for hemorrhoids, contrasting with numerous non-FDA-approved Rx and OTC products.
• NoveCite's iMSCs are believed to be differentiated and superior to donor-derived MSCs due to higher potency, unlimited supply, consistent quality, and higher expansion capability.
• Competitors for LYMPHIR include Mogamulizumab (Poteligeo), Brentuximab vedotin (Adcetris), Romidepsin (Istodax), and Vorinostat (Zolinza).
• Competitors for Mino-Lok include Defencath (CorMedix Inc.) and B-Lock (Great Lakes Pharmaceuticals, Inc.), though neither is approved for catheter salvage in bacteremic patients.
• NoveCite competes with Cynata Therapeutics Limited, Healios K.K., and Mesoblast Limited in the cell therapy field for ARDS.

Management Changes

Corporate Governance

Legal Proceedings

• Not involved in any litigation that is believed to have a material adverse effect on financial position or results of operations.
• No action, suit, proceeding, inquiry, or investigation pending or threatened against the company or its officers/directors.

Related Party Transactions

• Citius Pharma extended warrants held by its Chairman and Executive Vice Chairman on April 5, 2024, August 7, 2024, and September 25, 2024.
• Citius Pharma extended warrants held by its Chairman and Executive Vice Chairman on August 7, 2025.
• Citius Pharma is a guarantor of Citius Oncology's payment obligations under license and asset purchase agreements for LYMPHIR.
• Citius Pharma provides executive, operational, financial, and administrative support to Citius Oncology under a Shared Services Agreement, with a quarterly allocated expense of approximately $1,006,000.
• Citius Pharma sold one share of Series A Preferred Stock for $100 to Leonard Mazur (Chairman and CEO) on April 17, 2025, which was redeemed on June 9, 2025.
• Leonard Mazur (Chairman and CEO) personally guaranteed repayment of a $1,000,000 note payable from an unrelated lender, due January 2, 2026.
• An employee provided a $300,000 non-interest-bearing advance to the Company on May 28, 2025, and was repaid in full on June 5, 2025.
• The promissory note from Citius Oncology to Citius Pharma was amended on December 10, 2025, to tie its maturity to Citius Oncology closing capital raises of at least $50 million.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future equity raises; high volatility in stock price; risk of losing investment if liquidation occurs; no dividends expected.
• Employees: Retention challenges due to intense competition for qualified personnel; reliance on key management; potential impact on equity compensation plans if stock delisted.
• Customers/Patients: Potential for new treatment options (LYMPHIR, Mino-Lok, Halo-Lido) for serious conditions; access to LYMPHIR facilitated by J-code and distribution agreements.
• Creditors: Substantial doubt about going concern raises concerns about repayment of outstanding obligations (e.g., milestone payments, note payable).
• Suppliers/Partners: Risk of delayed or terminated support if company fails to meet contractual obligations, including timely payments.

Next Steps

• Citius Pharma continues to engage with the FDA to define the regulatory path forward for Mino-Lok.
• Citius Pharma will continue ongoing engagement with the FDA regarding the next steps of development for Halo-Lido.
• Preliminary results for the LYMPHIR Phase 1 trial at the University of Minnesota are anticipated in the first quarter of 2026.
• Citius Pharma intends to distribute Citius Oncology shares to its stockholders at a yet-to-be-determined date in the future, following the expiration of the six-month lockup period.
• Citius Pharma expects to need to access the capital markets in the near future for additional capital for research and development and for operations beyond March 2026.
• Citius Oncology expects the first commercial sale of LYMPHIR to occur in the first quarter of 2026 (which is December 2025 based on other mentions).

Key Dates

Recommendation

The company faces severe financial distress, evidenced by recurring net losses, negative working capital, and an explicit "going concern" warning from its auditors. While there are positive clinical developments and a product launch, the substantial outstanding liabilities, ongoing need for significant capital, and high stock price volatility present an extremely high-risk investment profile. The potential for significant dilution from future capital raises and the risk of delisting further compound these concerns. A seasoned investor would likely view the financial instability as outweighing the clinical progress, suggesting a "sell" or "avoid" stance until financial health significantly improves and the going concern uncertainty is resolved.

Keywords

Citius Pharmaceuticals, CTXR, Biopharmaceutical, Oncology, Anti-infectives, Stem Cell Therapy, LYMPHIR, Denileukin Diftitox, Cutaneous T-cell Lymphoma, Mino-Lok, Catheter-Related Bloodstream Infections, Halo-Lido, Hemorrhoids, NoveCite, ARDS, FDA Approval, Clinical Trials, Drug Development, Financial Losses, Going Concern, Capital Raise, Intellectual Property, Nasdaq